Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10383664 | 0.85 | KMT2A (0.36) | MEN1CYP1A2KMT2ATLR7MAT2A | |
| SCHEMBL1146282 | 0.84 | PDE4B (0.34) | MEN1CYP1A2KMT2ATLR7MAT2A | |
| SCHEMBL4298064 | 0.73 | KDM4E (0.31) | — | |
| SCHEMBL19539317 | 0.73 | ADORA2A (0.36) | MEN1CYP1A2KMT2ATLR7MAT2A | |
| Trifluoroacetic Acid SCHEMBL434419 | 0.73 | TLR7 (0.33) | TLR7 | |
| SCHEMBL20564 | 0.72 | ADORA3 (0.38) | KMT2AADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2953678 | 0.72 | ADORA3 (0.38) | ADORA2AADORA3 | |
| SCHEMBL12157588 | 0.72 | NCF1 (0.34) | TLR7 | |
| SCHEMBL731519 | 0.70 | TLR7 (0.41) | TLR7 | |
| SCHEMBL19539296 | 0.70 | TLR7 (0.52) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | MEN1 2161/4885CYP1A2 353/4885KMT2A 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.